You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨騰盛博藥(2137.HK)漲超7%續創新高 市值達368億港元
格隆匯 09-20 15:22
格隆匯9月20日丨騰盛博藥(2137.HK)逆勢拉昇漲超7%,盤中報51.5港元再度刷新歷史新高價,總市值達368億港元。騰盛博藥日前授出1509.75萬份購股權,行使價為每股47.60港元。此前新冠“特效藥”再獲進展,新冠中和抗體BRII-196/BRII-198聯合療法在837例疾病進展高風險的患者中,與安慰劑相比,住院及死亡的複合終點降低78%。目前這款新冠中和抗體藥物正在國際開展三期臨牀試驗。另外,9月上旬,公司宣佈追加1億美元投入,推進新冠中和抗體聯合療法BRII-196/198在全球的註冊申請和商業化進程。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account